Russell Schundler Sells 5,964 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 5,964 shares of Liquidia stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares in the company, valued at $7,738,984.57. This trade represents a 1.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Liquidia Trading Up 0.3 %

Shares of Liquidia stock opened at $13.72 on Friday. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The company has a market cap of $1.17 billion, a P/E ratio of -8.42 and a beta of 0.23. The company’s fifty day simple moving average is $14.65 and its two-hundred day simple moving average is $12.78.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Analysts predict that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in LQDA. Wellington Management Group LLP grew its stake in Liquidia by 12.5% in the third quarter. Wellington Management Group LLP now owns 179,923 shares of the company’s stock worth $1,799,000 after purchasing an additional 19,932 shares during the period. XTX Topco Ltd purchased a new stake in shares of Liquidia in the 3rd quarter worth about $323,000. Barclays PLC grew its position in shares of Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after buying an additional 72,591 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Liquidia by 855.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,393 shares of the company’s stock worth $2,354,000 after acquiring an additional 210,753 shares in the last quarter. Finally, DMC Group LLC lifted its position in Liquidia by 17.4% during the 4th quarter. DMC Group LLC now owns 16,302 shares of the company’s stock valued at $192,000 after acquiring an additional 2,419 shares during the period. Institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on LQDA. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a report on Thursday, March 20th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, March 20th. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $26.63.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).